Bioanalytical Studies: It Plays A Crucial Role In Drug Development

The research and development of a new medicine cost over $1 billion, and the drug may take up to ten years to reach the market. Creating compounds and analyzing all their attributes to evaluate the feasibility of picking one new chemical entity (NCE) to become a safe and effective medicine is known as drug discovery and development. Strategies in drug research and development procedures are changing dramatically. Pharmacokinetics (PK), for example, is becoming more critical in both processes. Furthermore, toxicokinetics is generally recognized as a vital component of toxicity testing. A sensitive and specific bioanalytical approach is required with the increased emphasis on PK/toxicokinetics and the increased potency of novel medications.

The advent of bioanalysis as a vital tool during drug discovery and development is well acknowledged and widely accepted. Over the last few decades, various assays for NCEs, including tests for critical metabolites, have been consistently developed to assist multiple stages of discovery and development. Furthermore, different analytical processes are available for prescription drugs (Rx) and generic goods.

Bioanalysis

The quantitative evaluation of a substance (drug) or its metabolite in biological fluids, primarily blood, plasma, serum, urine, or tissue extracts. A bioanalytical approach is made up of two major components.

Sample preparation is used to clean up a sample before analysis and concentrate a model to increase detection. This procedure is known as bioanalytical studies sample preparation when the pieces are biological fluids such as plasma, serum, or urine. The measurement of drug concentrations in bodily fluids provides data required to understand the time course of pharmacological action, or PK, in animals and humans and is an essential component of the drug discovery and development process.

A mass spectrometer is a preferred detector for detecting the chemical. Currently, the primary technology utilized in quantitative bioanalysis is high-performance liquid chromatography combined with tandem mass spectrometry (HPLC-MS/MS) employs either electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI). When used in the selected reaction monitoring (SRM) mode, the triple quadrupole (QqQ) mass spectrometer (MS) provides a one-of-a-kind combination of sensitivity, specificity, and dynamic range. As a result, the QqQ MS has become the instrument of choice for quantitation in the pharmaceutical sector. Because ESI and APCI may operate at flow rates as high as 1 and 2 mL/min, respectively, most convenience columns (e.g., C18, C8, C4, phenyl, cyanopropyl) are compatible.

Must Read: The Role of Assay Testing in Clinical Diagnostics

Parameters for validation

For quantitative methods, it is generally agreed that the following validation factors should be evaluated: selectivity, calibration model, stability, accuracy (bias, precision), and limit of quantification. LOD, recovery, repeatability, and ruggedness are other criteria that may need to be assessed (robustness).

Conclusion

Bioanalysis is now universally acknowledged as an essential component of pharmacokinetic/pharmacodynamic assessment. It begins with its discovery and continues through the many stages of drug development that leads to market authorization. It is intended to provide some broad views in this area that will serve as the foundation for a general framework for approaching bioanalysis from the beginning (i.e., identification of a lead molecule) and proceeding through various phases of drug development.